31st July 2018

European Medicines Agency grants licence for Aimovig

The Migraine Trust welcomes decision

The European Medicines Agency has granted a licence for the use of Aimovig® (erenumab) for the prevention of migraine in adults who experience at least four migraine days per month.

Aimovig is the first and only approved preventive treatment designed specifically for migraine that blocks the calcitonin gene-related peptide (CGRP) receptor, thought to be involved in the transmission of the pain signals associated with migraine.

Aimovig clinical trials in both episodic and chronic migraine populations have demonstrated significant reductions in mean monthly migraine days alongside a safety profile similar to placebo.

The Migraine Trust warmly welcomes this decision, with Wendy Thomas, Chief Executive of The Migraine Trust, commenting:

“The Migraine Trust was closely associated with the development of erenumab through the recruitment of patients for trials and by supporting research in this area over many years.

“We think this decision is wonderful as this new treatment has the potential to help many people with chronic and episodic migraine.

“Migraine is incredibly painful, and has symptoms that include vomiting and visual disturbance, so getting it frequently can literally ruin lives.

“That is why it is important that it becomes available to patients as soon as possible.”

It is currently going through a technology appraisal with the National Institute for Health and Care Excellence (NICE). NICE will then make recommendations on its use within the NHS.